Cutaneous Lupus Erythematosus (CLE) Clinical Trial
Official title:
A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00633945 -
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
|
N/A | |
| Recruiting |
NCT05411016 -
A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
|
Phase 1 | |
| Recruiting |
NCT01510067 -
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
|